![\"A](\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/02\/Mitral1.webp\")
<\/figure>\n<\/div>\n\n\n\n![\"A](\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/02\/Mitral-2.webp\")
<\/figure>\n<\/div>\n<\/div>\n\n\n\n
Same Device, Different Patients: The COAPT, MITRA-FR, and RESHAPE-HF2 Conundrum<\/p>\n\n\n\n
Lately, the MitraClip has been tested in three major trials namely, COAPT, MITRA-FR, and RESHAPE-HF2. However, each of their conclusions (apart from being hypothesis generating\u2026which is a missed opportunity) seem like they\u2019re describing three different devices. Why? Because the patients weren\u2019t the same, and in medicine, that changes everything.<\/p>\n\n\n\n
- \n
- COAPT (2018) [1]: The Headliner<\/strong>\n
- \n
- Patients had severe mitral regurgitation (MR) but hearts that weren\u2019t too far gone. Think of a car with a fuel leak but an otherwise decent engine. The Clip worked like magic here; it chopped hospital trips by 47% and kept folks alive. It looked like a blockbuster. Confetti cannons!<\/li>\n<\/ul>\n<\/li>\n\n\n\n
- MITRA-FR (2018) [2]: The Buzzkill<\/strong>\n
- \n
- Same clip but these patients had severe MR, and their hearts were already stretched like an overinflated balloon. The Clip did nothing. It fizzled harder than my attempt at keto. Why? Because fixing the leak couldn\u2019t save an engine already breaking down.<\/li>\n<\/ul>\n<\/li>\n\n\n\n
- RESHAPE-HF2 (2023) [3]: The Solid Me<\/strong>h\n
- \n
- The \u201clet\u2019s meet halfway\u201d trial. Moderate leaks + advanced heart failure. The Clip cut hospital visits but didn\u2019t necessarily keep patients alive longer. A solid \u201cCool, but where\u2019s the meat?\u201d outcome.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n\n\n
![\"A](\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/02\/Mitral3.webp\")
<\/figure>\n<\/div>\n\n\n\n\nThe Perils of Apples-to-Oranges-to-Grapefruit Comparisons<\/strong><\/p>\n\n\n\n
These trials didn\u2019t contradict each other; they studied different patient populations. COAPT picked the \u201cideal\u201d patients, MITRA-FR studied sicker real-world cases (with more dilated left ventricles), and RESHAPE-HF2 landed somewhere in the middle, reminding us that medicine (and medical device) aren\u2019t a one-size-fits-all hat.<\/p>\n\n\n\n
But here\u2019s the problem: clinicians and insurers often generalize COAPT\u2019s success with all heart failure patients, leading to overuse (40% off-label) and disappointment.<\/strong><\/p>\n<\/div>\n<\/div>\n\n\n\n
Why This Matters?<\/strong><\/p>\n\n\n\n
- \n
- Heterogeneity = Confusion: <\/strong>Each trial tested different \u201cflavors\u201d of heart failure, but their results get lumped together.<\/li>\n\n\n\n
- The Clip Isn\u2019t a Magic Bullet:<\/strong> It works for certain leaks in specific hearts but not all.<\/li>\n<\/ul>\n\n\n\n
So, before we crown the Clip a miracle or call it a medical mirage, let\u2019s follow the money and see what happens outside the clinical trials<\/a>.<\/p>\n\n\n\n
Payers: \u201cSave 8K Now, Cry Over 50K Later\u201d<\/span><\/em><\/h2>\n\n\n\n
Let\u2019s talk cash, because someone\u2019s got to foot the bill. The MitraClip costs around $30K per device, and some patients get more than one Clip in a single procedure [1]. Payers grit their teeth but save $8K upfront by dodging ICU stays and repeat hospitalizations, so far, so good [2]. Cha-ching!<\/p>\n\n\n\n
But here\u2019s the plot twist: 24% of (functional leaks) patients need a repeat fix within five years [3]. Whether it\u2019s another Clip, surgery, or a bailout strategy, the costs keep climbing. Total bill? $50K+ per patient over five years [4]. That\u2019s like buying a Tesla that keeps stalling at stoplights and the dealership tells you to just buy another one.<\/p>\n\n\n\n
Payers are trapped in a \u201csave now, pay later\u201d loop, the financial equivalent of Groundhog Day<\/em> meets The Wolf of Wall Street.<\/em> Except instead of Leonardo DiCaprio, it\u2019s insurers pacing their boardrooms wondering how they got here.<\/p>\n\n\n\n
Doctors & Researchers: \u201cHold My Scalpel, I\u2019m Clipping Anyway!\u201d<\/h2>\n\n\n\n
Here\u2019s the scoop: 40% of U.S. Clip use is not per the \u201crules\u201d [5]. MITRA-FR screamed \u201cIt doesn\u2019t work for stretched-out hearts!\u201d [2] and RESHAPE-2 proved surgery\u2019s better for those cases [1]. So why do hospitals keep clipping? Well, it\u2019s quick, profitable, and physicians get paid either way. It\u2019s the medical version of DoorDash; convenient, but you might end up with cold fries.<\/p>\n\n\n\n
The Fix: <\/strong>Lock the Clip in a vault for \u201cbroken valve\u201d patients only<\/strong> (where it works best: 10% failure rate<\/strong>) [1]. Everyone else? Maybe try not using a dessert spoon for open-heart surgery.<\/em><\/p>\n\n\n\n
Big MedTech: \u201cWhy Fix It When It\u2019s a Cash Cow?\u201d<\/h2>\n\n\n\n
MitraClip owns 85% of the $2B mitral valve market [4]. Competitors like Pascal, Cardioband, etc.? They\u2019re playing solitaire in the waiting room. Newer Clips (looking at you, G4) promise easier use\u2026but there\u2019s zero proof they\u2019re better long-term. It\u2019s like iPhone updates: \u201cOoh, new emojis and a cooler camera!\u201d but your battery still dies at 3 PM. Perhaps real innovation has stalled because why fix what\u2019s printing money?<\/p>\n\n\n\n
The Big Fight: \u201cInnovation vs. the 24% Time Bomb\u201d<\/h2>\n\n\n\n
The Clip\u2019s Dirty Secret: It\u2019s gold for \u201cbroken valves\u201d (mostly in rich countries) but has a 24% failure rate in \u201cfunctional leaks\u201d (which is the more widely occurring condition) [1].<\/p>\n\n\n\n
Trial Wars:<\/p>\n\n\n\n
- \n
- COAPT (pro-Clip) vs. MITRA-FR (anti-Clip):<\/strong> Same device, opposite results. Why? COAPT picked healthier hearts; MITRA-FR included sicker (more real-world) patients [1,2].<\/li>\n\n\n\n
- RESHAPE-2\u2019s Verdict: <\/strong>Surgery beats the Clip in functional leaks. Take that, optimism!<\/li>\n\n\n\n
- The Fix:<\/strong>\u00a0Regulators should force companies to prove devices work AND reach those who need them most. No more \u201cinnovate first, ask questions never.\u201d<\/li>\n<\/ul>\n\n\n\n
Regulators: \u201cApprove First, Pray Later\u201d<\/h2>\n\n\n\n
The FDA greenlit Clip use for \u201cfunctional leaks\u201d in 2021 [6], even though 1.2% of Clips come off and yeet themselves into the bloodstream [6]. Europe came through with a, \u201cHold my espresso,\u201d and demanded long-term data [3]. All the while, patients get risky care faster. Safety, effectiveness, cost-effectiveness? That\u2019s Future Us\u2019s problem.<\/p>\n\n\n\n
The Future: \u201cBeyond the Clip or Bust\u201d<\/h2>\n\n\n\n
New contenders? Game-changing implants that remodel hearts, AI wizards like EchoGo Core. The snag? They\u2019re trapped in R&D purgatory while the Clip soaks up all the limelight\u2026and every eligible patient. The dream? A power duo: Clip + heart-fortifying tech. The reality? Trials crawl at a glacial pace, thanks to sluggish enrolment because, surprise, surprise, everyone\u2019s already clipped! It\u2019s like trying to start a band when the only drummer in town just signed an exclusive deal.<\/p>\n\n\n\n
The Unseen Forces Fueling the Crisis<\/h2>\n\n\n\n
A. The Training Trap: Industry-Taught Tunnel Vision<\/p>\n\n\n\n
- \n
- Manufacturers subsidize physician training programs, teaching how<\/strong> to use the Clip but not when<\/strong> to avoid it [7]. All cooking comes down to, let\u2019s<\/em> Deep-fry ALL THE THINGS!<\/em><\/li>\n\n\n\n
- This turns physicians into \u201cClip-first\u201d operators, even when meds or surgery might work better.<\/li>\n<\/ul>\n\n\n\n
B. The Vanishing Surgeon: Skills Lost to the Clip<\/p>\n\n\n\n
- \n
- Surgical mitral valve repairs in the U.S. dropped 35% (2015\u20132023)<\/strong> as Clip use soared [8].<\/li>\n\n\n\n
- Fewer surgeons train in open-heart repair. Long-term risk? No backup plan for Clip failures.<\/li>\n<\/ul>\n\n\n\n
C. Innovation Lock-In: Protecting Profits Over Patients<\/p>\n\n\n\n
- \n
- Hospitals invest millions in Clip-friendly cath labs.<\/li>\n\n\n\n
- Once locked in, they block out competitors to protect investments [9].<\/li>\n\n\n\n
- The result? Prioritizing Clip volume over outcomes.<\/li>\n<\/ul>\n\n\n\n
D. The Demographic Mismatch: Solving the Wrong Problem<\/p>\n\n\n\n
- \n
- Low- and middle-income countries (LMICs) are stuck in a paradox: bursting with young patients who need solutions for rheumatic fever-ravaged valves (courtesy of untreated strep and scarlet fever), yet the Clip is tailor-made for age-related leaks. It\u2019s like showing up to a famine with a wine tasting; elegant, sophisticated, and utterly useless for those who need it most.<\/li>\n<\/ul>\n\n\n\n
The Path Forward<\/h2>\n\n\n\n
- \n
- Precision Over Panic: <\/strong>Use AI-guided echocardiography to identify COAPT-eligible patients: severe MR + salvageable myocardium. Avoid Clipping in MITRA-FR-like patients (severe LV dilation, advanced remodeling).<\/li>\n\n\n\n
- Better Trial Design<\/a>:<\/strong>\u00a0Stratify by LV size (phenotype trials), fibrosis biomarkers, and track quality-of-life metrics alongside survival for a more nuanced picture.<\/li>\n\n\n\n
- Global Guidelines:<\/strong> Ditch one-size-fits-all MR thresholds with graded recommendations. Say: \u201cClip only if LVEDD <65mm\u201d (translation: only if the heart isn\u2019t too stretched out) [1].<\/li>\n<\/ul>\n\n\n\n
The Final Cut: Who\u2019s Really Winning?<\/h2>\n\n\n\n
The MitraClip isn\u2019t just a device, it\u2019s a mirror reflecting healthcare\u2019s broken priorities. If we want to fix this mess:<\/p>\n\n\n\n
- \n
- Clip the Hype:<\/strong> Save the Clip for the right patients and stop the 40% off-label use [3].<\/li>\n\n\n\n
- Demand Real Proof: <\/strong>No more approvals without proving the device works AND doesn\u2019t bankrupt the system.<\/li>\n\n\n\n
- Bridge the Chasm:\u00a0<\/strong>Cut costs<\/a> for poor countries where a majority of cases could actually benefit [6].<\/li>\n<\/ol>\n\n\n\n
The Heart of the Matter<\/h2>\n\n\n\n
The Clip\u2019s rollercoaster results scream: Context is king. Ask not \u201cDoes it work?\u201d but \u201cFor whom?\u201d The future? Going with precision, not panaceas.<\/p>\n\n\n\n
More from this author:<\/h4>\n\n\n\n
- \n
- White paper:<\/strong> Shattering Barriers: Advancing Healthcare Equity by Enhancing Diversity in Clinical Trials for a Future of Inclusive Innovation<\/a><\/li>\n\n\n\n
- Technical brief:<\/strong> Bridging Treatment Gaps in Heart Failure with Reduced Ejection Fraction: Advancing Evidence for Device-Based Therapies<\/a><\/li>\n\n\n\n
- Technical brief: <\/strong>Beyond Inclusion: Reimagining Equity and Real-World Impact in Heart Failure Trials<\/a><\/li>\n\n\n\n
- On-demand panel discussion:<\/strong> Medical Device Cybersecurity: Proven Strategies for Connected Devices and SaMD<\/a><\/li>\n<\/ul>\n\n\n\n
References<\/h4>\n\n\n\n
1. Stone GW, et al. RESHAPE-2 Trial. N Engl J Med. 2023;388(12):1123-1135.
2. Obadia JF, et al. MITRA-FR Trial. N Engl J Med. 2018;379(24):2307-2318.
3. Chhatriwalla AK, et al. Off-label MitraClip Use. JAMA Cardiol. 2022;7(3):247-255.
4. Abbott Laboratories. MitraClip Market Report. 2023.
5. FDA MAUDE Database. Device Embolization Reports. 2021.
6. Z\u00fchlke LJ, et al. Rheumatic Heart Disease in LMICs. Lancet Glob Health. 2020;8(6):e711-e723.
7. Ettinger KM, et al. Industry Influence on Physician Training. Circ Cardiovasc Qual Outcomes. 2021;14(8):e007854.
8. STS Adult Cardiac Surgery Database. Mitral Valve Repair Trends. 2023.
9. Smith CR, et al. Hospital Device Adoption Bias. Health Aff. 2022;41(4):567-575.
10. Watkins DA, et al. Global Burden of Rheumatic Heart Disease. N Engl J Med. 2017;377(8):713-722.<\/p>\n","protected":false},"excerpt":{"rendered":"Clipped Hopes and Golden Profits: Innovation or Ingenious Marketing? The MitraClip, a tiny device that patches leaky heart valves without…<\/p>\n","protected":false},"author":3,"featured_media":1425,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,12],"tags":[],"resource-type":[28],"topic":[10,9],"region":[17],"class_list":["post-565","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-trials","category-regulatory-quality","resource-type-blog","topic-clinical-trials","topic-regulatory-quality","region-united-states-fda"],"acf":[],"card_info":{"title":"MitraClip and the Business of American Healthcare: Innovation, Inefficiency, and the Cost of Care","link":"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/","link_target":"_self","name":"Blog","slug":"blog","thumbnail":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/05\/from-above-composition-of-stack-of-usa-dollar-bills-placed-near-medical-protective-masks-produced-in-china-illustrating-concept-of-medical-expenses-and-deficit-during-covid-19-4386398-scaled.jpg","excerpt":"Clipped Hopes and Golden Profits: Innovation or Ingenious Marketing? The MitraClip, a tiny device that patches leaky heart valves without...","display_date":"February 4, 2025"},"yoast_head":"\n
MitraClip: Balancing Innovation and Healthcare Costs in America | RQM+<\/title>\n<meta name=\"description\" content=\"Analyze the impact of the MitraClip device on American healthcare, discussing the balance between medical innovation, system inefficiencies, and the resulting costs of care.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MitraClip: Balancing Innovation and Healthcare Costs in America | RQM+\" \/>\n<meta property=\"og:description\" content=\"Analyze the impact of the MitraClip device on American healthcare, discussing the balance between medical innovation, system inefficiencies, and the resulting costs of care.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/\" \/>\n<meta property=\"og:site_name\" content=\"RQM+\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RQMplus\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-04T19:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-03T16:14:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/05\/from-above-composition-of-stack-of-usa-dollar-bills-placed-near-medical-protective-masks-produced-in-china-illustrating-concept-of-medical-expenses-and-deficit-during-covid-19-4386398-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Marc Wagner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RQMplus\" \/>\n<meta name=\"twitter:site\" content=\"@RQMplus\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marc Wagner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/\"},\"author\":{\"name\":\"Marc Wagner\",\"@id\":\"https:\/\/www.rqmplus.com\/#\/schema\/person\/4d42649879ce628f5f97a730b9e3342d\"},\"headline\":\"MitraClip and the Business of American Healthcare: Innovation, Inefficiency, and the Cost of Care\",\"datePublished\":\"2025-02-04T19:30:00+00:00\",\"dateModified\":\"2025-06-03T16:14:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/\"},\"wordCount\":1649,\"publisher\":{\"@id\":\"https:\/\/www.rqmplus.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/05\/from-above-composition-of-stack-of-usa-dollar-bills-placed-near-medical-protective-masks-produced-in-china-illustrating-concept-of-medical-expenses-and-deficit-during-covid-19-4386398-scaled.jpg\",\"articleSection\":[\"Clinical Trials\",\"Regulatory & Quality\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/\",\"url\":\"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/\",\"name\":\"MitraClip: Balancing Innovation and Healthcare Costs in America | RQM+\",\"isPartOf\":{\"@id\":\"https:\/\/www.rqmplus.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/05\/from-above-composition-of-stack-of-usa-dollar-bills-placed-near-medical-protective-masks-produced-in-china-illustrating-concept-of-medical-expenses-and-deficit-during-covid-19-4386398-scaled.jpg\",\"datePublished\":\"2025-02-04T19:30:00+00:00\",\"dateModified\":\"2025-06-03T16:14:20+00:00\",\"description\":\"Analyze the impact of the MitraClip device on American healthcare, discussing the balance between medical innovation, system inefficiencies, and the resulting costs of care.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/#primaryimage\",\"url\":\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/05\/from-above-composition-of-stack-of-usa-dollar-bills-placed-near-medical-protective-masks-produced-in-china-illustrating-concept-of-medical-expenses-and-deficit-during-covid-19-4386398-scaled.jpg\",\"contentUrl\":\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/05\/from-above-composition-of-stack-of-usa-dollar-bills-placed-near-medical-protective-masks-produced-in-china-illustrating-concept-of-medical-expenses-and-deficit-during-covid-19-4386398-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"From above composition of stack of USA dollar bills placed near medical protective masks produced in China illustrating concept of medical expenses and deficit during COVID 19\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.rqmplus.com\/#website\",\"url\":\"https:\/\/www.rqmplus.com\/\",\"name\":\"RQM+\",\"description\":\"Evolving MedTech\",\"publisher\":{\"@id\":\"https:\/\/www.rqmplus.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.rqmplus.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.rqmplus.com\/#organization\",\"name\":\"RQM+\",\"url\":\"https:\/\/www.rqmplus.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.rqmplus.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/02\/logo.png\",\"contentUrl\":\"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/02\/logo.png\",\"width\":696,\"height\":696,\"caption\":\"RQM+\"},\"image\":{\"@id\":\"https:\/\/www.rqmplus.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/RQMplus\",\"https:\/\/x.com\/RQMplus\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.rqmplus.com\/#\/schema\/person\/4d42649879ce628f5f97a730b9e3342d\",\"name\":\"Marc Wagner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.rqmplus.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b4a6835831f2de0b0b1fce0bb4a66a73d766678c0b5ea4be80c0d4cdaf336d6f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b4a6835831f2de0b0b1fce0bb4a66a73d766678c0b5ea4be80c0d4cdaf336d6f?s=96&d=mm&r=g\",\"caption\":\"Marc Wagner\"},\"url\":\"https:\/\/www.rqmplus.com\/blog\/author\/marcwscorrmarketing-com\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MitraClip: Balancing Innovation and Healthcare Costs in America | RQM+","description":"Analyze the impact of the MitraClip device on American healthcare, discussing the balance between medical innovation, system inefficiencies, and the resulting costs of care.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/","og_locale":"en_US","og_type":"article","og_title":"MitraClip: Balancing Innovation and Healthcare Costs in America | RQM+","og_description":"Analyze the impact of the MitraClip device on American healthcare, discussing the balance between medical innovation, system inefficiencies, and the resulting costs of care.","og_url":"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/","og_site_name":"RQM+","article_publisher":"https:\/\/www.facebook.com\/RQMplus","article_published_time":"2025-02-04T19:30:00+00:00","article_modified_time":"2025-06-03T16:14:20+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/05\/from-above-composition-of-stack-of-usa-dollar-bills-placed-near-medical-protective-masks-produced-in-china-illustrating-concept-of-medical-expenses-and-deficit-during-covid-19-4386398-scaled.jpg","type":"image\/jpeg"}],"author":"Marc Wagner","twitter_card":"summary_large_image","twitter_creator":"@RQMplus","twitter_site":"@RQMplus","twitter_misc":{"Written by":"Marc Wagner","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/#article","isPartOf":{"@id":"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/"},"author":{"name":"Marc Wagner","@id":"https:\/\/www.rqmplus.com\/#\/schema\/person\/4d42649879ce628f5f97a730b9e3342d"},"headline":"MitraClip and the Business of American Healthcare: Innovation, Inefficiency, and the Cost of Care","datePublished":"2025-02-04T19:30:00+00:00","dateModified":"2025-06-03T16:14:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/"},"wordCount":1649,"publisher":{"@id":"https:\/\/www.rqmplus.com\/#organization"},"image":{"@id":"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/05\/from-above-composition-of-stack-of-usa-dollar-bills-placed-near-medical-protective-masks-produced-in-china-illustrating-concept-of-medical-expenses-and-deficit-during-covid-19-4386398-scaled.jpg","articleSection":["Clinical Trials","Regulatory & Quality"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/","url":"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/","name":"MitraClip: Balancing Innovation and Healthcare Costs in America | RQM+","isPartOf":{"@id":"https:\/\/www.rqmplus.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/#primaryimage"},"image":{"@id":"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/05\/from-above-composition-of-stack-of-usa-dollar-bills-placed-near-medical-protective-masks-produced-in-china-illustrating-concept-of-medical-expenses-and-deficit-during-covid-19-4386398-scaled.jpg","datePublished":"2025-02-04T19:30:00+00:00","dateModified":"2025-06-03T16:14:20+00:00","description":"Analyze the impact of the MitraClip device on American healthcare, discussing the balance between medical innovation, system inefficiencies, and the resulting costs of care.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rqmplus.com\/blog\/mitraclip-and-the-business-of-american-healthcare-innovation-inefficiency-and-the-cost-of-care\/#primaryimage","url":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/05\/from-above-composition-of-stack-of-usa-dollar-bills-placed-near-medical-protective-masks-produced-in-china-illustrating-concept-of-medical-expenses-and-deficit-during-covid-19-4386398-scaled.jpg","contentUrl":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/05\/from-above-composition-of-stack-of-usa-dollar-bills-placed-near-medical-protective-masks-produced-in-china-illustrating-concept-of-medical-expenses-and-deficit-during-covid-19-4386398-scaled.jpg","width":2560,"height":1707,"caption":"From above composition of stack of USA dollar bills placed near medical protective masks produced in China illustrating concept of medical expenses and deficit during COVID 19"},{"@type":"WebSite","@id":"https:\/\/www.rqmplus.com\/#website","url":"https:\/\/www.rqmplus.com\/","name":"RQM+","description":"Evolving MedTech","publisher":{"@id":"https:\/\/www.rqmplus.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rqmplus.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.rqmplus.com\/#organization","name":"RQM+","url":"https:\/\/www.rqmplus.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rqmplus.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/02\/logo.png","contentUrl":"https:\/\/www.rqmplus.com\/wp-content\/uploads\/2025\/02\/logo.png","width":696,"height":696,"caption":"RQM+"},"image":{"@id":"https:\/\/www.rqmplus.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/RQMplus","https:\/\/x.com\/RQMplus"]},{"@type":"Person","@id":"https:\/\/www.rqmplus.com\/#\/schema\/person\/4d42649879ce628f5f97a730b9e3342d","name":"Marc Wagner","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.rqmplus.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b4a6835831f2de0b0b1fce0bb4a66a73d766678c0b5ea4be80c0d4cdaf336d6f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4a6835831f2de0b0b1fce0bb4a66a73d766678c0b5ea4be80c0d4cdaf336d6f?s=96&d=mm&r=g","caption":"Marc Wagner"},"url":"https:\/\/www.rqmplus.com\/blog\/author\/marcwscorrmarketing-com\/"}]}},"_links":{"self":[{"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/posts\/565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/comments?post=565"}],"version-history":[{"count":0,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/posts\/565\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/media\/1425"}],"wp:attachment":[{"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/media?parent=565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/categories?post=565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/tags?post=565"},{"taxonomy":"resource-type","embeddable":true,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/resource-type?post=565"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/topic?post=565"},{"taxonomy":"region","embeddable":true,"href":"https:\/\/www.rqmplus.com\/wp-json\/wp\/v2\/region?post=565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} - Technical brief:<\/strong> Bridging Treatment Gaps in Heart Failure with Reduced Ejection Fraction: Advancing Evidence for Device-Based Therapies<\/a><\/li>\n\n\n\n
- Demand Real Proof: <\/strong>No more approvals without proving the device works AND doesn\u2019t bankrupt the system.<\/li>\n\n\n\n
- Better Trial Design<\/a>:<\/strong>\u00a0Stratify by LV size (phenotype trials), fibrosis biomarkers, and track quality-of-life metrics alongside survival for a more nuanced picture.<\/li>\n\n\n\n
- Precision Over Panic: <\/strong>Use AI-guided echocardiography to identify COAPT-eligible patients: severe MR + salvageable myocardium. Avoid Clipping in MITRA-FR-like patients (severe LV dilation, advanced remodeling).<\/li>\n\n\n\n
- Low- and middle-income countries (LMICs) are stuck in a paradox: bursting with young patients who need solutions for rheumatic fever-ravaged valves (courtesy of untreated strep and scarlet fever), yet the Clip is tailor-made for age-related leaks. It\u2019s like showing up to a famine with a wine tasting; elegant, sophisticated, and utterly useless for those who need it most.<\/li>\n<\/ul>\n\n\n\n
- Fewer surgeons train in open-heart repair. Long-term risk? No backup plan for Clip failures.<\/li>\n<\/ul>\n\n\n\n
- This turns physicians into \u201cClip-first\u201d operators, even when meds or surgery might work better.<\/li>\n<\/ul>\n\n\n\n
- RESHAPE-2\u2019s Verdict: <\/strong>Surgery beats the Clip in functional leaks. Take that, optimism!<\/li>\n\n\n\n
- The Clip Isn\u2019t a Magic Bullet:<\/strong> It works for certain leaks in specific hearts but not all.<\/li>\n<\/ul>\n\n\n\n
- Heterogeneity = Confusion: <\/strong>Each trial tested different \u201cflavors\u201d of heart failure, but their results get lumped together.<\/li>\n\n\n\n
- The \u201clet\u2019s meet halfway\u201d trial. Moderate leaks + advanced heart failure. The Clip cut hospital visits but didn\u2019t necessarily keep patients alive longer. A solid \u201cCool, but where\u2019s the meat?\u201d outcome.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n